FDA Accepts Iloperidone NDA

The FDA has accepted Vanda Pharmaceuticals’ new drug application (NDA) for iloperidone, an investigational atypical antipsychotic for the treatment of schizophrenia.

Acceptance of the application confirms that the application is sufficiently complete for FDA review, Vanda said.

The company has two other candidates in clinical development — VEC-162, which is in Phase III trials to treat sleep and mood disorders, and VSF-173, which is in Phase II development to treat excessive sleepiness.